What if the biggest risk in your clinical supply chain isn’t forecasting, recruitment volatility, or vendor performance — but the silent erosion of data integrity every time information changes hands?

We talk endlessly about systems, platforms, and digital transformation. Yet the real cracks often appear in the mundane moments: a spreadsheet emailed instead of uploaded, a protocol amendment not fully cascaded, a depot update that lags by 48 hours, or a manual adjustment that never makes it back into the “source of truth.”

Each handoff introduces friction. Each friction point introduces interpretation. And interpretation is where risk quietly compounds.

In a global, multi‑partner ecosystem, data doesn’t just move — it mutates. By the time it reaches the decision‑maker, it may be technically “accurate” but operationally misleading. That gap is where over‑shipments, shortages, expiry exposure, and patient risk are born.

The organizations that win aren’t the ones with the most tools. They’re the ones with the cleanest handoffs, the clearest ownership, and the discipline to protect data integrity as a strategic asset — not an afterthought.

If we want to elevate clinical supply, we must stop treating data as a byproduct of operations and start treating it as the backbone of risk management.

Because the real risk isn’t bad data — it’s data that was good three handoffs ago.

#ClinicalSupplyChain #ClinicalTrials #SupplyChainExcellence #PharmaLeadership #DataIntegrity #RiskManagement #LifeSciences post Week 7